CN101605543A - 具有校正突变-cftr加工活性的化合物及其应用 - Google Patents

具有校正突变-cftr加工活性的化合物及其应用 Download PDF

Info

Publication number
CN101605543A
CN101605543A CNA2006800150356A CN200680015035A CN101605543A CN 101605543 A CN101605543 A CN 101605543A CN A2006800150356 A CNA2006800150356 A CN A2006800150356A CN 200680015035 A CN200680015035 A CN 200680015035A CN 101605543 A CN101605543 A CN 101605543A
Authority
CN
China
Prior art keywords
pharmaceutical composition
phenyl
cftr
pharmaceutically acceptable
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800150356A
Other languages
English (en)
Chinese (zh)
Inventor
A·弗克曼
N·佩德蒙特
L·J·V·加里耶塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CN101605543A publication Critical patent/CN101605543A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
CNA2006800150356A 2005-03-18 2006-03-08 具有校正突变-cftr加工活性的化合物及其应用 Pending CN101605543A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66350105P 2005-03-18 2005-03-18
US60/663,501 2005-03-18

Publications (1)

Publication Number Publication Date
CN101605543A true CN101605543A (zh) 2009-12-16

Family

ID=37024308

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800150356A Pending CN101605543A (zh) 2005-03-18 2006-03-08 具有校正突变-cftr加工活性的化合物及其应用

Country Status (12)

Country Link
US (1) US8143295B2 (US20080318984A1-20081225-C00062.png)
EP (1) EP1863522A4 (US20080318984A1-20081225-C00062.png)
JP (1) JP2008538107A (US20080318984A1-20081225-C00062.png)
KR (1) KR20070114820A (US20080318984A1-20081225-C00062.png)
CN (1) CN101605543A (US20080318984A1-20081225-C00062.png)
AU (1) AU2006227833A1 (US20080318984A1-20081225-C00062.png)
BR (1) BRPI0608453A2 (US20080318984A1-20081225-C00062.png)
CA (1) CA2600869A1 (US20080318984A1-20081225-C00062.png)
IL (1) IL185999A0 (US20080318984A1-20081225-C00062.png)
MX (1) MX2007011512A (US20080318984A1-20081225-C00062.png)
RU (1) RU2007138584A (US20080318984A1-20081225-C00062.png)
WO (1) WO2006101740A2 (US20080318984A1-20081225-C00062.png)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892764A (zh) * 2010-03-25 2013-01-23 弗特克斯药品有限公司 (r)-1(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1h-吲哚-5-基)环丙烷甲酰胺的固体形式
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN108463223A (zh) * 2015-10-09 2018-08-28 艾伯维公司 用于治疗囊性纤维化的增效剂-校正剂组合
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PT2489659T (pt) 2004-06-24 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
CA2635214A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
BRPI0620960A2 (pt) 2005-12-28 2011-11-29 Vertex Pharmaceuticals Incorporated formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
KR20100016073A (ko) 2007-04-02 2010-02-12 인스티튜트 포 원월드 헬스 Ｃｆｔｒ 억제제 화합물 및 이의 용도
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
WO2009023509A2 (en) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
SI2195312T1 (sl) 2007-10-09 2013-01-31 Merck Patent Gmbh Derivati piridina, uporabni kot aktivatorji glukokinaze
US8389736B2 (en) * 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
PL2578571T3 (pl) 2007-11-16 2016-03-31 Vertex Pharma Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
DK2615085T3 (en) 2008-03-31 2015-10-05 Vertex Pharma Pyridyl derivatives as CFTR modulators
EP2278879B1 (en) * 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131952A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising thiazole derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
MX2011008131A (es) * 2009-02-02 2012-01-20 Chromocell Corp Lineas celulares que expresan cftr y los métodos para utilizarlas.
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
NZ708598A (en) 2010-04-07 2017-05-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d](1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
SI2555754T1 (sl) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Trdne farmacevtske oblike 3-(6-(1-(2,2-difluoro-benzo(d)(1,3)dioksol-5- il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
CN104478800A (zh) 2010-09-14 2015-04-01 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
JP6182136B2 (ja) 2011-06-29 2017-08-16 ヤンセン ファーマシューティカ エヌ．ベー． マトリックスメタロプロテアーゼのアロステリックなプロセシング阻害因子を設計、選択及び／又は最適化するための方法
EP2726073A1 (en) * 2011-06-29 2014-05-07 Janssen Pharmaceutica, N.V. Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
CA2840202A1 (en) 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
IN2014KN00885A (US20080318984A1-20081225-C00062.png) 2011-11-08 2015-10-02 Vertex Pharma
SI2806859T1 (sl) 2012-01-25 2019-11-29 Vertex Pharma Formulacije 3-(6-(1-(2.2-difluorobenzo(d)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2914248B2 (en) 2012-11-02 2023-10-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201405991D0 (en) * 2014-04-03 2014-05-21 Cambridge Entpr Ltd Novel compounds
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
JP6896619B2 (ja) 2014-10-06 2021-06-30 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーター
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
WO2016087665A2 (en) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2016123253A1 (en) * 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey Hydrazne derivatives for the treatment of cancer
US10729671B2 (en) 2015-01-27 2020-08-04 Rutgers, The State University Of New Jersey Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
US10604480B2 (en) 2015-01-27 2020-03-31 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer
US10221133B2 (en) 2015-01-27 2019-03-05 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer
ITUB20153714A1 (it) * 2015-09-18 2017-03-18 Luigina Romani Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.
WO2016129005A1 (en) * 2015-02-09 2016-08-18 Luigina Romani Thymosin alpha 1 for use in treatment of cystic fibrosis
CA3088229A1 (en) 2018-01-11 2019-07-18 Genethon Combination treatment of sarcoglycanopathies
MX2021002653A (es) 2018-09-09 2021-09-23 Qanatpharma Ag Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares.
KR102399037B1 (ko) * 2020-01-06 2022-05-17 성균관대학교산학협력단 아민화된 아진의 신규한 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069154B1 (en) * 1981-01-13 1986-10-15 Mitsui Toatsu Kagaku Kabushiki Kaisha Novel thiazole compounds, process for their preparation, and medicinal composition containing same
JPS649935A (en) * 1987-06-30 1989-01-13 Kyowa Hakko Kogyo Kk Remedy for hepatopathy
EP0519449A1 (en) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
SE0201837D0 (sv) 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239867B2 (en) 2006-04-07 2019-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10987348B2 (en) 2006-04-07 2021-04-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN102892764A (zh) * 2010-03-25 2013-01-23 弗特克斯药品有限公司 (r)-1(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1h-吲哚-5-基)环丙烷甲酰胺的固体形式
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN102892764B (zh) * 2010-03-25 2016-07-06 弗特克斯药品有限公司 (r)-1(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1h-吲哚-5-基)环丙烷甲酰胺的固体形式
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN108463223A (zh) * 2015-10-09 2018-08-28 艾伯维公司 用于治疗囊性纤维化的增效剂-校正剂组合

Also Published As

Publication number Publication date
WO2006101740A2 (en) 2006-09-28
IL185999A0 (en) 2008-08-07
KR20070114820A (ko) 2007-12-04
MX2007011512A (es) 2007-12-07
EP1863522A4 (en) 2010-11-10
EP1863522A2 (en) 2007-12-12
JP2008538107A (ja) 2008-10-09
US20080318984A1 (en) 2008-12-25
RU2007138584A (ru) 2009-04-27
BRPI0608453A2 (pt) 2009-12-29
WO2006101740A3 (en) 2009-06-04
US8143295B2 (en) 2012-03-27
AU2006227833A1 (en) 2006-09-28
CA2600869A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
CN101605543A (zh) 具有校正突变-cftr加工活性的化合物及其应用
US20080319008A1 (en) Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
US20070265316A1 (en) Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
US8389736B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
JP7097874B2 (ja) リシルオキシダーゼ様２阻害剤の使用
US20230241050A1 (en) Applications of hpk1 kinase inhibitor in preventing and/or treating animal pathogen infection
WO2009051910A1 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US11123349B2 (en) Method of treatment
BRPI0707409A2 (pt) uso de derivados da naftiridina como medicamentos
CN104379180A (zh) 用cyld抑制剂治疗中耳炎及其它病状的组合物和方法
BR112019011334A2 (pt) uso de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais
US11129831B2 (en) Identification of agents displaying functional activation of dopamine D2 and D4 receptors
CN103301064B (zh) 一种白介素-2或其衍生物鼻喷剂及其制备方法
TW201033225A (en) Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
CN108159043B (zh) 西瑞香素在制药中的应用及药物制剂
US20220040189A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2013075892A (ja) 抗炎症及び／又は抗ヒスタミン剤組成物
CN113827597B (zh) 化合物在制备治疗特发性肺纤维化的药物中的应用
EP4209226A1 (en) Use of polypeptide in drug for preventing and treating pneumonia
TWI554272B (zh) 包含阿卡波糖之醫藥組合物及其用於免疫調節之用途
US9073863B2 (en) Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
CN112587526A (zh) 1,3,4-噻二唑苯基呋喃硫代甲酸酯类化合物在制备α-葡萄糖苷酶抑制剂中的应用
CN115813921A (zh) 化合物16f16及其衍生物在制备抗乙型肝炎病毒药物中的应用
WO2012166654A1 (en) Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
WO2016192098A1 (zh) 包含阿卡波糖之医药组合物及其用于免疫调节之用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091216